Omeros Shares Fall After BofA Downgrade
12:59PM ET 6/08/2022 MT NewswiresOmeros (OMER) shares are down nearly 11% in early afternoon trading after the biopharmaceutical company's stock was downgraded by BofA Securities. The firm...
Quotes Snapshot > OMER
Omeros Corp OMER:NASDAQ
Last Price$4.49Cboe Closing Price as of 4:24PM ET 7/01/22
Cboe Real-Time Quotes
Cboe Real-Time Quotes
Today's Change+1.74(63.27%)
Bid (Size)$4.05 (100)
Ask (Size)$5.74 (100)
Day Low / High$2.77 - 4.83
Volume12.5 M
Read more news Recent News
--BofA Securities Downgrades Omeros to Neutral From Buy, Sets $4 Price Target
9:32AM ET 6/08/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Omeros Says Results of Study Evaluating Narsoplimab Published in Journal of Clinical Oncology
11:49AM ET 4/20/2022 MT NewswiresOmeros (OMER) said Wednesday the results of a study evaluating the efficacy and safety of its investigational drug narsoplimab to treat hematopoietic stem...
Omeros Q4 Adjusted Loss Widens in Wake of Omidria Sale
5:21PM ET 3/01/2022 MT NewswiresOmeros (OMER) reported a Q4 adjusted net loss of $0.37 per share late Tuesday, compared with a loss of $0.36 per share in Q3. The biopharmaceutical...
View all Commentary and Analysis
Omeros: On Death's Door
12:47AM ET 6/02/2022 Seeking AlphaOmeros Corporation (OMER) CEO Greg Demopulos on Q1 2022 Results - Earnings Call Transcript
10:26PM ET 5/10/2022 Seeking AlphaOmeros: The Weight Of The Wait, A Conundrum
10:18PM ET 5/02/2022 Seeking AlphaOmeros Corporation's (OMER) CEO Greg Demopulos On Q4 2021 Results - Earnings Call Transcript
8:01PM ET 3/01/2022 Seeking AlphaCompany Profile
Business DescriptionOmeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA. View company web site for more details
| Address | The Omeros Building Seattle, Washington 98119 |
| Phone | +1 206 676-5000 |
| Number of Employees | 236 |
| Recent SEC Filing | 06/24/2022 8-K |
| Chairman, President & Chief Executive Officer | Gregory A. Demopulos |
| Chief Financial Officer, Treasurer & VP | Michael A. Jacobsen |
| Chief Scientific Officer & Vice President-Science | George A. Gaitanaris |
| Chief Medical Officer & Vice President | J. Steven Whitaker |
Company Highlights
| Price Open | $2.80 |
| Previous Close | $2.75 |
| 52 Week Range | $1.86 - 16.57 |
| Market Capitalization | $281.7 M |
| Shares Outstanding | 62.7 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/08/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | 0.83 |
| Earnings per Share | -$1.75 |
| Beta vs. S&P 500 | N/A |
| Revenue | $29.9 M |
| Net Profit Margin | -234.76% |
| Return on Equity | 112.70% |
Analyst Ratings as of 06/08/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |